Manhattan Bridge Capital - LOAN Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Manhattan Bridge Capital in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LOAN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LOAN, but not buy additional shares or sell existing shares.
View LOAN analyst ratings or view top-rated stocks.

Manhattan Bridge Capital's stock was trading at $5.33 at the beginning of 2023. Since then, LOAN shares have decreased by 2.6% and is now trading at $5.19.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 13th 2023.
View our LOAN earnings forecast.

Manhattan Bridge Capital, Inc. (NASDAQ:LOAN) announced its quarterly earnings data on Friday, March, 11th. The credit services provider reported $0.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by $0.01. Manhattan Bridge Capital had a trailing twelve-month return on equity of 13.80% and a net margin of 60.53%.

Manhattan Bridge Capital announced a quarterly dividend on Monday, March 13th. Investors of record on Monday, April 10th will be given a dividend of $0.112 per share on Monday, April 17th. This represents a $0.45 dividend on an annualized basis and a yield of 8.63%. The ex-dividend date is Thursday, April 6th.
Read our dividend analysis for LOAN.

Manhattan Bridge Capital (NASDAQ:LOAN) pays an annual dividend of $0.50 per share and currently has a dividend yield of 9.60%. LOAN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 104.17%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for LOAN.

Based on aggregate information from My MarketBeat watchlists, some companies that other Manhattan Bridge Capital investors own include Allena Pharmaceuticals (ALNA), Energy Transfer (ET), AcelRx Pharmaceuticals (ACRX), Actinium Pharmaceuticals (ATNM), B&G Foods (BGS), Enterprise Products Partners (EPD), Global Medical REIT (GMRE), Kimco Realty (KIM), Mylan (MYL) and Rigel Pharmaceuticals (RIGL).

Manhattan Bridge Capital trades on the NASDAQ under the ticker symbol "LOAN."

Manhattan Bridge Capital's stock is owned by a variety of retail and institutional investors. Top institutional investors include Moneta Group Investment Advisors LLC (92.66%), Bard Associates Inc. (3.36%), Shufro Rose & Co. LLC (1.72%), Waddell & Associates LLC (1.10%), Bellwether Advisors LLC (1.08%) and Renaissance Technologies LLC (1.07%). Insiders that own company stock include Assaf Ran, Lyron L Bentovim and Michael Jackson.
View institutional ownership trends.

Shares of LOAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LOAN stock can currently be purchased for approximately $5.19.

Manhattan Bridge Capital (NASDAQ:LOAN) has a market capitalization of $59.63 million and generates $8.57 million in revenue each year. The credit services provider earns $5.21 million in net income (profit) each year or $0.48 on an earnings per share basis.

Manhattan Bridge Capital's mailing address is 60 CUTTER MILL RD. SUITE 205, GREAT NECK NY, 11021. The official website for the company is www.manhattanbridgecapital.com. The credit services provider can be reached via phone at (516) 444-3400 or via fax at 516-444-3404.